{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:52:39Z","timestamp":1769579559646,"version":"3.49.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"DOI":"10.1093\/jac\/dkw522","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T20:05:49Z","timestamp":1479326749000},"page":"dkw522","source":"Crossref","is-referenced-by-count":12,"title":["Estimated generic prices for novel treatments for drug-resistant tuberculosis"],"prefix":"10.1093","author":[{"given":"Dzintars","family":"Gotham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Fortunak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Pozniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Frederick E.","family":"Nytko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,1,10]]},"reference":[{"key":"2017011017351413000_dkw522v1.1","unstructured":"World Health Organization. Global Tuberculosis Report 2014. http:\/\/www.who.int\/tb\/publications\/global_report\/gtbr14_main_text.pdf."},{"key":"2017011017351413000_dkw522v1.2","unstructured":"World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberulosis. http:\/\/apps.who.int\/medicinedocs\/documents\/s21662en\/s21662en.pdf."},{"key":"2017011017351413000_dkw522v1.3","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.13.122028"},{"key":"2017011017351413000_dkw522v1.4","unstructured":"World Health Organization. The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis - Interim Policy Guidance. http:\/\/apps.who.int\/iris\/bitstream\/10665\/137334\/1\/WHO_HTM_TB_2014.23_eng.pdf."},{"key":"2017011017351413000_dkw522v1.5","unstructured":"European Medicines Agency. Sirturo. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002614\/human_med_001730.jsp&mid=WC0b01ac058001d124."},{"key":"2017011017351413000_dkw522v1.6","unstructured":"World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. http:\/\/apps.who.int\/iris\/bitstream\/10665\/84879\/1\/9789241505482_eng.pdf."},{"key":"2017011017351413000_dkw522v1.7","unstructured":"World Health Organization. 19th WHO Model List of Essential Medicines. http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/EML2015_8-May-15.pdf?ua=1."},{"key":"2017011017351413000_dkw522v1.8","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-353"},{"key":"2017011017351413000_dkw522v1.9","unstructured":"TB Alliance. Global Phase 3 \u2018STAND\u2019 Trial Launched to Test New Tuberculosis Drug Regimen PaMZ to Shorten, Improve Treatment. http:\/\/www.tballiance.org\/newscenter\/view-brief.php?id=1116."},{"key":"2017011017351413000_dkw522v1.10","unstructured":"ClinicalTrials.gov. A Phase 2 Open Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects with Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02193776."},{"key":"2017011017351413000_dkw522v1.11","unstructured":"ClinicalTrials.gov. A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects with Drug Resistant Pulmonary Tuberculosis. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02333799."},{"key":"2017011017351413000_dkw522v1.12","unstructured":"ClinicalTrials.gov. Treatment Shortening of MDR-TB Using Existing and New Drugs (MDR-END). https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02619994."},{"key":"2017011017351413000_dkw522v1.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00193413"},{"key":"2017011017351413000_dkw522v1.14","unstructured":"MSF Access campaign. DR-TB Drugs Under the Microscope: Sources and Prices for Drug-Resistant Tuberculosis Medicines, 4th edn. http:\/\/www.msfaccess.org\/sites\/default\/files\/TB_report__DR-TB_DRUGS_UTM__4th_edition_2016.pdf."},{"key":"2017011017351413000_dkw522v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.12.012"},{"key":"2017011017351413000_dkw522v1.16","unstructured":"MSF Access campaign. Untangling the Web of Price Reductions, 3rd edn. http:\/\/d2pd3b5abq75bb.cloudfront.net\/2012\/07\/16\/15\/13\/21\/885\/UTW_3_ENG_Dec2002.pdf."},{"key":"2017011017351413000_dkw522v1.17","unstructured":"MSF Access campaign. Untangling the Web of Price Reductions, 18th ed. http:\/\/www.msfaccess.org\/sites\/default\/files\/MSF_assets\/HIV_AIDS\/Docs\/HIV_report_Untangling-the-Wed-18thed_ENG_2016.pdf."},{"key":"2017011017351413000_dkw522v1.18","unstructured":"AIDS Medicines and Diagnostics Service. Antiretroviral Medicines in Low- and Middle-Income Countries: Forecasts of Global and Regional Demand for 2012\u20132015. http:\/\/apps.who.int\/iris\/bitstream\/10665\/83148\/1\/9789241505468_eng.pdf."},{"key":"2017011017351413000_dkw522v1.19","unstructured":"Infodrive India. India Export Data and Top Export Products from India. http:\/\/www.infodriveindia.com\/india-exports-trade-data.aspx."},{"key":"2017011017351413000_dkw522v1.20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27641"},{"key":"2017011017351413000_dkw522v1.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009586"},{"key":"2017011017351413000_dkw522v1.22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu012"},{"key":"2017011017351413000_dkw522v1.23","unstructured":"Stop TB Partnership. Global Drug Facility Product Catalogue. http:\/\/www.stoptb.org\/gdf\/drugsupply\/pc2.asp?CLevel=2&CParent=4."},{"key":"2017011017351413000_dkw522v1.24","unstructured":"Global Drug Facility. Buying Quality, Affordable Tuberculosis Drugs Through the Global Drug Facility. http:\/\/www.stoptb.org\/assets\/documents\/gdf\/whatis\/FS%20DP%20Brochure%20FINAL.pdf."},{"key":"2017011017351413000_dkw522v1.25","unstructured":"Government of India National Pharmaceutical Pricing Authority. Norms for Conversion Cost (CC), Packing Charges (PC) and Process Loss (PL). http:\/\/nppaindia.nic.in\/normsccpcpl.html."},{"key":"2017011017351413000_dkw522v1.26","unstructured":"UNITAID. HIV Medicines Technology and Market Landscape-1st Edition. 2014. http:\/\/www.unitaid.eu\/images\/marketdynamics\/publications\/HIV-Meds-\u00a0Landscape-March2014.pdf."},{"key":"2017011017351413000_dkw522v1.27","unstructured":"World Health Organization. Guideline on Submission of Documentation for Prequalification of Multisource (Generic) Finished Pharmaceutical Products (FPPs) Approved by Stringent Regulatory Authorities (SRAs). http:\/\/apps.who.int\/prequal\/info_applicants\/Guidelines\/PQProcGenericSRA_July2011.pdf."},{"key":"2017011017351413000_dkw522v1.28","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"2017011017351413000_dkw522v1.29","unstructured":"MSF Access campaign. Untangling the Web of Antiretroviral Price Reductions, 17th edn. http:\/\/msfaccess.org\/content\/untangling-web-antiretroviral-price-reductions-17th-edition-%E2%80%93-july-2014."},{"key":"2017011017351413000_dkw522v1.30","unstructured":"Stop TB Partnership. Annual Report 2014. http:\/\/www.stoptb.org\/assets\/documents\/resources\/publications\/annualreports\/STOPTB_annualeport_2014_\u00a0web.pdf."},{"key":"2017011017351413000_dkw522v1.31","unstructured":"DR-TB STAT. About. http:\/\/drtb-stat.org\/about\/."},{"key":"2017011017351413000_dkw522v1.32","unstructured":"Stop TB Partnership. The Bedaquiline Donation Program. http:\/\/www.stoptb.org\/gdf\/drugsupply\/bedaquilineDonation.asp."},{"key":"2017011017351413000_dkw522v1.33","unstructured":"M\u00e9decins Sans Fronti\u00e8res. Developing Countries Hit with High Price for Important New Tuberculosis Drug. http:\/\/www.msf.org\/article\/access-developing-countries-hit-high-price-important-new-tuberculosis-drug."},{"key":"2017011017351413000_dkw522v1.34","unstructured":"Stop TB Partnership. Stop TB Partnership\u2019s Global Drug Facility Jumpstarts Access to New Drugs for MDR-TB with Innovative Public-Private Partnerships. http:\/\/www.stoptb.org\/news\/stories\/2016\/ns16_005.asp."},{"key":"2017011017351413000_dkw522v1.35","unstructured":"World Bank. GNI Per Capita, Atlas Method (Current US$). http:\/\/data.worldbank.org\/indicator\/NY.GNP.PCAP.CD."},{"key":"2017011017351413000_dkw522v1.36","unstructured":"PricewaterhouseCoopers. The Changing Dynamics of Pharma Outsourcing in Asia: Are You Readjusting Your Sights? https:\/\/www.pwc.be\/en\/pharma\/the-changing-dynamics-of-pharma-outsourcing-in-asia.pdf."},{"key":"2017011017351413000_dkw522v1.37","unstructured":"Zhang J , Comparing China\u2019s and India\u2019s Pharmaceutical Manufacturing. Pharmaceutical Online. http:\/\/www.pharmaceuticalonline.com\/doc\/comparing-china-s-and-india-s-pharmaceutical-manufacturing-0001."},{"key":"2017011017351413000_dkw522v1.38","unstructured":"World Health Organization. WHO List of Prequalified Medicinal Products. http:\/\/apps.who.int\/prequal\/query\/productregistry.aspx?list=ha."},{"key":"2017011017351413000_dkw522v1.39","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-13-35"},{"key":"2017011017351413000_dkw522v1.40","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-14-15"},{"key":"2017011017351413000_dkw522v1.41","unstructured":"Medicines Patent Pool. The Medicines Patent Pool Expands Mandate to Hepatitis C and Tuberculosis Treatment. http:\/\/www.medicinespatentpool.org\/the-medicines-patent-pool-expands-mandate-to-hepatitis-c-and-tuberculosis-treatment\/."}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T19:46:01Z","timestamp":1485200761000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkw522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,10]]},"references-count":41,"alternative-id":["10.1093\/jac\/dkw522"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkw522","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,10]]}}}